3 High-Yielding U.S. Pharmaceutical Companies to Consider
The stock market has been bullish for years now, and most companies are richly valued as a result. Meanwhile, dividend yields remain low -- right now, the SPDR S&P 500 ETF (NYSEMKT: SPY) offers just 1.7%.
What's an investor seeking returns to do?
One attractive option is the pharmaceutical sector, where some large-cap companies are maintaining the winning trifecta of a stable dividend yield, ongoing earnings growth, and attractive valuation. For these three businesses in particular, company-specific events including acquisitions and new drugs make for particularly enticing prospects. Let's take a look at AbbVie (NYSE: ABBV), Bristol-Myers Squibb (NYSE: BMY), and Gilead Sciences (NASDAQ: GILD).
Source Fool.com
